Clinical Characterization of Monoallelic-PKHD1 Subjects
Tabinda Jawaid(Mayo Clinic), Peter C. Harris(Mayo Clinic), Sarah R. Senum(Mayo Clinic), Charles D. Madsen(Mayo Clinic), Vicente E. Torres(Mayo Clinic in Arizona), Christian Hanna(Mayo Clinic)
Cited by 0
Related Papers
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Mutations in GANAB , Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease
|The American Journal of Human Genetics|2016|463
Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca <sup>2+</sup> -permeable nonselective cation channel
|Proceedings of the National Academy of Sciences|2000|447
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
|Journal of Clinical Investigation|2012|444
Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease
|The American Journal of Human Genetics|2018|310